- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04590118
Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)
A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Multicenter, Blind, Randomized, Placebo Controlled Single Injection of It-hMSC in Patients With Ischemic Stroke
Study Overview
Detailed Description
Stroke is a leading cause of disability. According to the comprehensive standardized prevalence estimation in 2016, 12.42 million people older than 40 years in China are currently suffering from stroke or have ever suffered from stroke. The overall prevalence rate of stroke in China was 1,596 per 100,000 people in 2016, 4.6 times higher than the rate of 345.1 per 100,000 people in 2013 and 70% of the survivors have disabilities in varying degrees. In addition to rehabilitation therapy, there is no therapeutic drugs of remarkable curative effect for the treatment of ischemic stroke patients. The latest data show that the annual recurrence rate of ischemic stroke in China is as high as 17.7%.
Allogeneic mesenchymal stem cells have been used in many clinical studies for different diseases. In addition to differentiating into multiple cell types and promoting the recovery and repair of the brain by replacing damaged cells, mesenchymal stem cells also secrete cytokines and neurotrophic factors to support and stimulate the growth of other endogenous cells. Meanwhile, mesenchymal stem cells also have anti-inflammatory and immunomodulatory functions. These characteristics of mesenchymal stem cells provide a new therapy for the treatment of stroke.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100070
- Recruiting
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Yongjun Wang, MD
- Phone Number: 010-59978538
- Email: yongjunwang1962@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older.
- Clinical diagnosis of ischemic stroke for more than 6 months.
- Imaging findings suggestive of ischemic stroke with functional deficits at initial diagnosis and enrollment.
- Severe neurological impairment associated with the diagnosis of ischemic stroke that resulted in the subject needing assistance to walk or not being able to perform general daily activities independently.
- No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment.
- NIHSS score between 6-20.
- Life expectancy longer than 12 months.
- Prior to treatment, the patient received standard medical care for secondary prevention of ischemic stroke, including but not limited to appropriate blood pressure and cholesterol control measures, use of antiplatelet agents or anticoagulants (except when prohibited).
- Understand and provide signed informed consent, or have a designated legal guardian or spouse make such decision voluntarily on behalf of the subject.
- Expected that the patient will receive standard medical care for secondary prevention of ischemic stroke and participate in all planned safe follow-up visits reasonably.
- Organ function as defined by the following criteria:
AST ≤ 2.5×ULN ALT ≤ 2.5×ULN TSB ≤1.5×ULN PT ≤1.25×ULN and PTT ≤1.25×ULN in subjects who did not receive antithrombotic therapy Serum albumin ≥ 3.0g/dL ANC ≥ 1,500/μL Platelets ≥ 150,000/μL Hemoglobin ≥ 9.0g/dL Serum creatinine ≤ 1.5×ULN Serum amylase or lipase ≤ 1.0×ULN
Exclusion Criteria:
- History of epilepsy.
- History of cancer.
- History of brain trauma and brain tumor.
- Positive for hepatitis B surface antigen, E antigen, E antibody, core antibody, hepatitis C, HIV or RPR.
- Myocardial infarction occurred within six months of study entry.
- Any other medical problems of clinical significance, abnormal mental or test results that the investigator or sponsor determined participating in the study pose a safety risk to the subject.
- Imaging findings suggestive of subarachnoid hemorrhage or intracerebral hemorrhage in the past 12 months.
- Participation in any study of experimental drug or device within 3 months.
- Participation in other study related to stem cell-therapy.
- History of drug or alcohol abuse within 1 year.
- Pregnant, lactating or planning to become pregnant during the trial.
- Allergic to cattle or pork products.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: it-hMSC
Single intravenous infusion of 0.5×10^6, 1×10^6, 2×10^6 it-hMSC/kg
|
Single intravenous infusion of it-hMSC for ischemic stroke patients
|
Placebo Comparator: Placebo-controlled: Placebo
Single intravenous infusion of 1 ml/kg placebo
|
Single intravenous infusion of 1 ml/kg placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale
Time Frame: month 1, month 3, month 6, month 9, month 12
|
The change from the baseline in Modified Rankin Scale will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available. The scale is divided into 7 degrees, from 0 (no deficit) to 6 (dead). |
month 1, month 3, month 6, month 9, month 12
|
National Institute of Health stroke scale
Time Frame: month 1, month 3, month 6, month 9, month 12
|
The change from the baseline in National Institute of Health stroke scale will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available. The range of scores is from 0 (normal) to 42. |
month 1, month 3, month 6, month 9, month 12
|
Mini-mental State Examination
Time Frame: month 1, month 3, month 6, month 9, month 12
|
The change from the baseline in Mini-mental State Examination will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available. The range of scores is from 0 to 30 (normal). |
month 1, month 3, month 6, month 9, month 12
|
Barthel Index
Time Frame: month 1, month 3, month 6, month 9, month 12
|
The change from the baseline in Barthel Index will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available. The range of scores is from 0 to 100 (normal). |
month 1, month 3, month 6, month 9, month 12
|
Geriatric Depression Scale
Time Frame: month 1, month 3, month 6, month 9, month 12
|
The change from the baseline in Geriatric Depression Scale will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available. The range of scores is from 0 (normal) to 10. |
month 1, month 3, month 6, month 9, month 12
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STCMSC-CT-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on it-hMSC
-
Ruijin HospitalCellular Biomedicine Group Ltd.UnknownAcute Respiratory Distress SyndromeChina
-
MetroHealth Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Terminated
-
Bernard (Barry) BaumelCompleted
-
Benjamin Van Voorhees, MD, MPHNorthwestern University; NorthShore University HealthSystem; Advocate Health... and other collaboratorsCompletedMajor Depression | Depressive EpisodesUnited States
-
Stemedica Cell Technologies, Inc.bioRASI, LLCRecruiting
-
University of Texas at AustinBaylor College of Medicine; University of Kansas Medical CenterCompleted
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Artery Disease | Critical Limb IschemiaAustria
-
Oslo University HospitalCentre for Appearance Research, University of the West of England, UKEnrolling by invitationBurns | Cleft Lip and Palate | Craniofacial Abnormalities | Skin Condition | Other Conditions Leading to a Visible DifferenceNorway
-
University of AarhusUnknownDysfunction of Vestibular SystemDenmark